Holmström, Morten Orebo http://orcid.org/0000-0002-3764-8578
Hasselbalch, Hans Carl
Funding for this research was provided by:
Kræftens Bekæmpelse (R149-A10159)
Article History
Received: 28 May 2018
Accepted: 12 June 2018
First Online: 9 July 2018
Compliance with ethical standards
:
: No authors have conflict of interest to disclose. However, it should be noted that Morten Orebo Holmström and Hans Carl Hasselbalch together with Mads Hald Andersen have filed a patent regarding theCALRexon 9 mutations andJAK2V61F mutation as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to Danish Law concerning inventions made at public research institutions.